PDF herunterladen
Semin Respir Crit Care Med 2011; 32(4): 409-422
DOI: 10.1055/s-0031-1283281
© Thieme Medical Publishers

Influenza Drug Resistance

Andrés Pizzorno1 , Yacine Abed1 , Guy Boivin1
  • 1Research Center in Infectious Diseases, Centre hospitalier Univeritaire de Quebec and Laval University, Québec City, Québec, Canada
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
19. August 2011 (online)

    Lizenzen und Reprints

ABSTRACT

Influenza viruses are major human pathogens with a global distribution, accounting for more than 500,000 annual deaths worldwide and with considerable impact on the quality of life and productivity of the society. Due to the limited efficacy of vaccination, antiviral drugs constitute a complementary approach in the control and prevention of influenza infections and thus play an important role in the management of influenza outbreaks and pandemics. Currently, adamantanes and neuraminidase inhibitors (NAIs) are the only two classes of anti-influenza agents approved for clinical use. However, the worldwide emergence and high prevalence of adamantane-resistant virus variants has discouraged the use of the former drugs. NAIs have proved to be very effective against influenza A and B viruses. Nevertheless, oseltamivir-resistant strains have also been reported quite frequently, as in the case of seasonal H1N1 viruses that circulated between 2007 and 2009. Indeed, the emergence of drug-resistant virus variants is always a matter of concern because it could significantly compromise the usefulness of such intervention. This highlights the need for continuous monitoring of resistance markers, as well as the development of new anti-influenza drugs and combination therapies.

KEYWORDS

Influenza - antivirals - resistance - adamantanes - neuraminidase inhibitors - oseltamivir - zanamivir - peramivir

REFERENCES

  • 1 Hayden F, Palese P. Influenza virus. In: Richman D D, Whiley R J, Hayden F G, eds. Clinical Virology. 2nd ed. Washington, DC: ASM Press; 2002: 891-920
    Google Scholar
  • 2 Claas E C, de Jong J C, van Beek R, Rimmelzwaan G F, Osterhaus A D. Human influenza virus A/HongKong/156/97 (H5N1) infection.  Vaccine. 1998;  16 (9–10) 977-978
    CrossrefPubMedGoogle Scholar
  • 3 Claas E C, Osterhaus A D, van Beek R al.. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus.  Lancet. 1998;  351 (9101) 472-477
    CrossrefPubMedGoogle Scholar
  • 4 Yuen K Y, Chan P K, Peiris M et al.. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus.  Lancet. 1998;  351 (9101) 467-471
    CrossrefPubMedGoogle Scholar
  • 5 Koopmans M, Wilbrink B, Conyn M et al.. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands.  Lancet. 2004;  363 (9409) 587-593
    CrossrefPubMedGoogle Scholar
  • 6 Peiris M, Yuen K Y, Leung C W et al.. Human infection with influenza H9N2.  Lancet. 1999;  354 (9182) 916-917
    CrossrefPubMedGoogle Scholar
  • 7 Uyeki T M, Chong Y H, Katz J M et al.. Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China 1999.  Emerg Infect Dis. 2002;  8 (2) 154-159
    CrossrefPubMedGoogle Scholar
  • 8 Neuzil K M, Zhu Y, Griffin M R et al.. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study.  J Infect Dis. 2002;  185 (2) 147-152
    CrossrefPubMedGoogle Scholar
  • 9 Centers for Disease Control and Prevention (CDC) . Estimates of deaths associated with seasonal influenza—United States, 1976–2007.  MMWR Morb Mortal Wkly Rep. 2010;  59 (33) 1057-1062
    PubMedGoogle Scholar
  • 10 World Healh Organization (WHO) .Influenza fact sheet No. 211. April 2009. http://www.who.int/mediacentre/factsheets/fs211/en/index.html Accessed February 2011
    Google Scholar
  • 11 Harper S A, Bradley J S, Englund J A Expert Panel of the Infectious Diseases Society of America et al. Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America.  Clin Infect Dis. 2009;  48 (8) 1003-1032
    CrossrefPubMedGoogle Scholar
  • 12 Monto A S, Ohmit S E, Hornbuckle K, Pearce C L. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes.  Antimicrob Agents Chemother. 1995;  39 (10) 2224-2228
    CrossrefPubMedGoogle Scholar
  • 13 Martin K, Helenius A. Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import.  Cell. 1991;  67 (1) 117-130
    CrossrefPubMedGoogle Scholar
  • 14 Hay A J, Wolstenholme A J, Skehel J J, Smith M H. The molecular basis of the specific anti-influenza action of amantadine.  EMBO J. 1985;  4 (11) 3021-3024
    PubMedGoogle Scholar
  • 15 Pielak R M, Chou J J. Flu channel drug resistance: a tale of two sites.  Protein Cell. 2010;  1 (3) 246-258
    CrossrefPubMedGoogle Scholar
  • 16 Couch R B. Prevention and treatment of influenza.  N Engl J Med. 2000;  343 (24) 1778-1787
    CrossrefPubMedGoogle Scholar
  • 17 Kawai N, Ikematsu H, Iwaki N et al.. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season.  Clin Infect Dis. 2005;  40 (9) 1309-1316
    CrossrefPubMedGoogle Scholar
  • 18 Keyser L A, Karl M, Nafziger A N, Bertino Jr J S. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.  Arch Intern Med. 2000;  160 (10) 1485-1488
    CrossrefPubMedGoogle Scholar
  • 19 Lynch III J P, Walsh E E. Influenza: evolving strategies in treatment and prevention.  Semin Respir Crit Care Med. 2007;  28 (2) 144-158
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 20 Klimov A I, Rocha E, Hayden F G, Shult P A, Roumillat L F, Cox N J. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis.  J Infect Dis. 1995;  172 (5) 1352-1355
    CrossrefPubMedGoogle Scholar
  • 21 Masuda H, Suzuki H, Oshitani H et al.. Incidence of amantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan.  Microbiol Immunol. 2000;  44 (10) 833-839
    PubMedGoogle Scholar
  • 22 Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient.  Clin Infect Dis. 2002;  34 (5) E23-E25
    CrossrefPubMedGoogle Scholar
  • 23 Saito R, Sakai T, Sato I et al.. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2.  J Clin Microbiol. 2003;  41 (5) 2164-2165
    CrossrefPubMedGoogle Scholar
  • 24 Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza.  J Infect Dis. 2003;  188 (1) 57-61
    CrossrefPubMedGoogle Scholar
  • 25 Centers for Disease Control and Prevention (CDC) . Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.  MMWR Morb Mortal Wkly Rep. 2009;  58 (16) 433-435
    PubMedGoogle Scholar
  • 26 Ziegler T, Hemphill M L, Ziegler M L et al.. Low incidence of rimantadine resistance in field isolates of influenza A viruses.  J Infect Dis. 1999;  180 (4) 935-939
    CrossrefPubMedGoogle Scholar
  • 27 Bright R A, Medina M J, Xu X et al.. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.  Lancet. 2005;  366 (9492) 1175-1181
    CrossrefPubMedGoogle Scholar
  • 28 Deyde V M, Xu X, Bright R A et al.. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.  J Infect Dis. 2007;  196 (2) 249-257
    CrossrefPubMedGoogle Scholar
  • 29 Cheung C L, Rayner J M, Smith G J et al.. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.  J Infect Dis. 2006;  193 (12) 1626-1629
    CrossrefPubMedGoogle Scholar
  • 30 Sweet C, Hayden F G, Jakeman K J, Grambas S, Hay A J. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets.  J Infect Dis. 1991;  164 (5) 969-972
    CrossrefPubMedGoogle Scholar
  • 31 Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations.  Antimicrob Agents Chemother. 2005;  49 (2) 556-559
    CrossrefPubMedGoogle Scholar
  • 32 Hayden F G, Belshe R B, Clover R D, Hay A J, Oakes M G, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.  N Engl J Med. 1989;  321 (25) 1696-1702
    CrossrefPubMedGoogle Scholar
  • 33 World Health Organization (WHO) .WHO guidelines for pharmacological management of pandemic influenza A (H1N1) 2009 and other influenza viruses. February 2010. http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf Accessed March 2011
    Google Scholar
  • 34 Griffin J A, Basak S, Compans R W. Effects of hexose starvation and the role of sialic acid in influenza virus release.  Virology. 1983;  125 (2) 324-334
    CrossrefPubMedGoogle Scholar
  • 35 Liu C, Eichelberger M C, Compans R W, Air G M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding.  J Virol. 1995;  69 (2) 1099-1106
    PubMedGoogle Scholar
  • 36 Matrosovich M N, Matrosovich T Y, Gray T, Roberts N A, Klenk H D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium.  J Virol. 2004;  78 (22) 12665-12667
    CrossrefPubMedGoogle Scholar
  • 37 Colman P M, Varghese J N, Laver W G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase.  Nature. 1983;  303 (5912) 41-44
    CrossrefPubMedGoogle Scholar
  • 38 Baker A T, Varghese J N, Laver W G, Air G M, Colman P M. Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus.  Proteins. 1987;  2 (2) 111-117
    CrossrefPubMedGoogle Scholar
  • 39 Burmeister W P, Ruigrok R W, Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid.  EMBO J. 1992;  11 (1) 49-56
    PubMedGoogle Scholar
  • 40 Mendel D B, Roberts N A. In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors.  Curr Opin Infect Dis. 1998;  11 (6) 727-732
    CrossrefPubMedGoogle Scholar
  • 41 Sidwell R W, Smee D F. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza.  Expert Opin Investig Drugs. 2002;  11 (6) 859-869
    CrossrefPubMedGoogle Scholar
  • 42 Ferraris O, Kessler N, Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.  Antiviral Res. 2005;  68 (1) 43-48
    CrossrefPubMedGoogle Scholar
  • 43 Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.  Antiviral Res. 2002;  54 (3) 143-147
    CrossrefPubMedGoogle Scholar
  • 44 Naughtin M, Dyason J C, Mardy S, Sorn S, von Itzstein M, Buchy P. Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus.  Antimicrob Agents Chemother. 2011;  55 (5) 2004-2010
    CrossrefPubMedGoogle Scholar
  • 45 Sheu T G, Deyde V M, Okomo-Adhiambo M et al.. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.  Antimicrob Agents Chemother. 2008;  52 (9) 3284-3292
    CrossrefPubMedGoogle Scholar
  • 46 U.S. Food and Drug Administration (FDA) .Relenza prescribing information. January 2008. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm183783.htm Accessed April 2011
    Google Scholar
  • 47 U.S. Food and Drug Administration (FDA) .Tamiflu prescribing information. January 2008. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095044.htm Accessed April 2011
    Google Scholar
  • 48 Barroso L, Treanor J, Gubareva L, Hayden F G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.  Antivir Ther. 2005;  10 (8) 901-910
    PubMedGoogle Scholar
  • 49 Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza.  N Engl J Med. 2009;  361 (23) 2204-2207
    CrossrefPubMedGoogle Scholar
  • 50 BioCryst Pharmaceuticals, Inc .BioCryst's partner Shionogi receives marketing and manufacturing approval for peramivir in Japan. January 13, 2010. http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=437335 Accessed February 2011
    Google Scholar
  • 51 Abed Y, Bourgault A M, Fenton R J et al.. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene.  J Infect Dis. 2002;  186 (8) 1074-1080
    CrossrefPubMedGoogle Scholar
  • 52 McKimm-Breschkin J L. Resistance of influenza viruses to neuraminidase inhibitors—a review.  Antiviral Res. 2000;  47 (1) 1-17
    CrossrefPubMedGoogle Scholar
  • 53 Russell R J, Haire L F, Stevens D J et al.. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.  Nature. 2006;  443 (7107) 45-49
    CrossrefPubMedGoogle Scholar
  • 54 Kiso M, Mitamura K, Sakai-Tagawa Y et al.. Resistant influenza A viruses in children treated with oseltamivir: descriptive study.  Lancet. 2004;  364 (9436) 759-765
    CrossrefPubMedGoogle Scholar
  • 55 Ives J A, Carr J A, Mendel D B et al.. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.  Antiviral Res. 2002;  55 (2) 307-317
    CrossrefPubMedGoogle Scholar
  • 56 Tai C Y, Escarpe P A, Sidwell R W et al.. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.  Antimicrob Agents Chemother. 1998;  42 (12) 3234-3241
    PubMedGoogle Scholar
  • 57 Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.  Antiviral Res. 2007;  74 (2) 159-162
    CrossrefPubMedGoogle Scholar
  • 58 Taylor N R, von Itzstein M. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis.  J Med Chem. 1994;  37 (5) 616-624
    CrossrefPubMedGoogle Scholar
  • 59 Moscona A. Oseltamivir resistance—disabling our influenza defenses.  N Engl J Med. 2005;  353 (25) 2633-2636
    CrossrefPubMedGoogle Scholar
  • 60 Barnett J M, Cadman A, Burrell F M et al.. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir.  Virology. 1999;  265 (2) 286-295
    CrossrefPubMedGoogle Scholar
  • 61 Baum E Z, Wagaman P C, Ly L et al.. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding.  Antiviral Res. 2003;  59 (1) 13-22
    CrossrefPubMedGoogle Scholar
  • 62 Weinstock D M, Gubareva L V, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient.  N Engl J Med. 2003;  348 (9) 867-868
    CrossrefPubMedGoogle Scholar
  • 63 Le Q M, Kiso M, Someya K et al.. Avian flu: isolation of drug-resistant H5N1 virus.  Nature. 2005;  437 (7062) 1108
    CrossrefPubMedGoogle Scholar
  • 64 de Jong M D, Tran T T, Truong H K et al.. Oseltamivir resistance during treatment of influenza A (H5N1) infection.  N Engl J Med. 2005;  353 (25) 2667-2672
    CrossrefPubMedGoogle Scholar
  • 65 World Health Organization (WHO) . Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010.  Wkly Epidemiol Rec. 2009;  85 (6) 37-40
    PubMedGoogle Scholar
  • 66 Ison M G, Gubareva L V, Atmar R L, Treanor J, Hayden F G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.  J Infect Dis. 2006;  193 (6) 760-764
    CrossrefPubMedGoogle Scholar
  • 67 Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.  Clin Infect Dis. 2006;  43 (12) 1555-1561
    CrossrefPubMedGoogle Scholar
  • 68 Whitley R J, Hayden F G, Reisinger K S et al.. Oral oseltamivir treatment of influenza in children.  Pediatr Infect Dis J. 2001;  20 (2) 127-133
    PubMedGoogle Scholar
  • 69 Carr S, Ilyushina N A, Franks J et al.. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer.  Pediatr Infect Dis J. 2011;  30 (4) 284-288
    PubMedGoogle Scholar
  • 70 Hurt A C, Holien J K, Parker M, Kelso A, Barr I G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.  J Virol. 2009;  83 (20) 10366-10373
    CrossrefPubMedGoogle Scholar
  • 71 Dapat C, Suzuki Y, Saito R et al.. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs.  Emerg Infect Dis. 2010;  16 (3) 493-496
    PubMedGoogle Scholar
  • 72 Gubareva L V. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.  Virus Res. 2004;  103 (1–2) 199-203
    CrossrefPubMedGoogle Scholar
  • 73 Gubareva L V, Matrosovich M N, Brenner M K, Bethell R C, Webster R G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.  J Infect Dis. 1998;  178 (5) 1257-1262
    CrossrefPubMedGoogle Scholar
  • 74 Oakley A J, Barrett S, Peat T S et al.. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.  J Med Chem. 2010;  53 (17) 6421-6431
    CrossrefPubMedGoogle Scholar
  • 75 Abed Y, Goyette N, Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.  Antivir Ther. 2004;  9 (4) 577-581
    PubMedGoogle Scholar
  • 76 Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.  Antivir Ther. 2006;  11 (8) 971-976
    PubMedGoogle Scholar
  • 77 Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.  J Infect Dis. 2011;  203 (1) 25-31
    CrossrefPubMedGoogle Scholar
  • 78 Yen H L, Hoffmann E, Taylor G et al.. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.  J Virol. 2006;  80 (17) 8787-8795
    CrossrefPubMedGoogle Scholar
  • 79 Jackson D, Barclay W, Zürcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations.  J Antimicrob Chemother. 2005;  55 (2) 162-169
    CrossrefPubMedGoogle Scholar
  • 80 McKimm-Breschkin J, Trivedi T, Hampson A et al.. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.  Antimicrob Agents Chemother. 2003;  47 (7) 2264-2272
    CrossrefPubMedGoogle Scholar
  • 81 Roberts N A. Treatment of influenza with neuraminidase inhibitors: virological implications.  Philos Trans R Soc Lond B Biol Sci. 2001;  356 (1416) 1895-1897
    PubMedGoogle Scholar
  • 82 Mungall B A, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000–2002 influenza seasons.  Virus Res. 2004;  103 (1-2) 195-197
    CrossrefPubMedGoogle Scholar
  • 83 Monto A S, McKimm-Breschkin J L, Macken C et al.. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.  Antimicrob Agents Chemother. 2006;  50 (7) 2395-2402
    CrossrefPubMedGoogle Scholar
  • 84 Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.  J Antimicrob Chemother. 2005;  55 (Suppl 1) i5-i21
    CrossrefPubMedGoogle Scholar
  • 85 Hauge S H, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08.  Emerg Infect Dis. 2009;  15 (2) 155-162
    CrossrefPubMedGoogle Scholar
  • 86 Meijer A, Lackenby A, Hungnes O European Influenza Surveillance Scheme et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season.  Emerg Infect Dis. 2009;  15 (4) 552-560
    CrossrefPubMedGoogle Scholar
  • 87 Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007—lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses.  Euro Surveill. 2009;  14 ((5). pii) 19112
    PubMedGoogle Scholar
  • 88 Dharan N J, Gubareva L V, Meyer J J Oseltamivir-Resistance Working Group et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.  JAMA. 2009;  301 (10) 1034-1041
    CrossrefPubMedGoogle Scholar
  • 89 Centers for Disease Control and Prevention (CDC) . Update: influenza activity—United States, September 28, 2008–April 4, 2009, and composition of the 2009-10 influenza vaccine.  MMWR Morb Mortal Wkly Rep. 2009;  58 (14) 369-374
    PubMedGoogle Scholar
  • 90 Nguyen H T, Sheu T G, Mishin V P, Klimov A I, Gubareva L V. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.  Antimicrob Agents Chemother. 2010;  54 (9) 3671-3677
    CrossrefPubMedGoogle Scholar
  • 91 World Health Organization (WHO) .Weekly update on oseltamivir resistance in influenza A(H1N1) 2009 viruses. April 6, 2011. http://www.who.int/csr/disease/influenza/2011_04_08_weekly_web_update_oseltamivir_resistance.pdf Accessed April 2011
    Google Scholar
  • 92 Centers for Disease Control and Prevention (CDC) . Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis—North Carolina, 2009.  MMWR Morb Mortal Wkly Rep. 2009;  58 (35) 969-972
    PubMedGoogle Scholar
  • 93 Nguyen H T, Fry A M, Loveless P A, Klimov A I, Gubareva L V. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir.  Clin Infect Dis. 2010;  51 (8) 983-984
    CrossrefPubMedGoogle Scholar
  • 94 Lackenby A, Moran Gilad J, Pebody R et al.. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11.  Euro Surveill. 2011;  16 (5) 16
    PubMedGoogle Scholar
  • 95 Herlocher M L, Truscon R, Elias S et al.. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.  J Infect Dis. 2004;  190 (9) 1627-1630
    CrossrefPubMedGoogle Scholar
  • 96 Baz M, Abed Y, Simon P, Hamelin M E, Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.  J Infect Dis. 2010;  201 (5) 740-745
    CrossrefPubMedGoogle Scholar
  • 97 Rameix-Welti M A, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.  PLoS Pathog. 2008;  4 (7) e1000103
    CrossrefPubMedGoogle Scholar
  • 98 Ciancio B C, Meerhoff T J, Kramarz P et al.. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses.  Euro Surveill. 2009;  14 (46) 14
    PubMedGoogle Scholar
  • 99 Bloom J D, Gong L I, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.  Science. 2010;  328 (5983) 1272-1275
    CrossrefPubMedGoogle Scholar
  • 100 Hamelin M E, Baz M, Abed Y et al.. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets.  PLoS Pathog. 2010;  6 (7) e1001015
    CrossrefPubMedGoogle Scholar
  • 101 Hamelin M E, Baz M, Bouhy X et al.. Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.  Antivir Ther. 2011;  In press
    PubMedGoogle Scholar
  • 102 Gristina G, Nardi G, Orazi D et al.. Prone positioning and intravenous zanamivir may represent effective alternatives for patients with severe ARDS virus A (H1N1) related pneumonia in hospitals with no access to ECMO.  Crit Care Res Pract. 2010;  2010 146456
    PubMedGoogle Scholar
  • 103 Härter G, Zimmermann O, Maier L et al.. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus.  Clin Infect Dis. 2010;  50 (9) 1249-1251
    CrossrefPubMedGoogle Scholar
  • 104 Dohna-Schwake C, Schweiger B, Felderhoff-Müser U et al.. Severe H1N1 infection in a pediatric liver transplant recipient treated with intravenous zanamivir: efficiency and complications.  Transplantation. 2010;  90 (2) 223-224
    PubMedGoogle Scholar
  • 105 Busani S, Girardis M, Biagioni E, Pasetto A, Sambri V. Surfactant therapy and intravenous zanamivir in severe respiratory failure due to persistent influenza A/H1N1 2009 virus infection.  Am J Respir Crit Care Med. 2010;  182 (10) 1334
    PubMedGoogle Scholar
  • 106 Brown A N, McSharry J J, Weng Q, Adams J R, Kulawy R, Drusano G L. Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.  Antimicrob Agents Chemother. 2011;  55 (4) 1740-1746
    CrossrefPubMedGoogle Scholar
  • 107 GlaxoSmithKline .GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza. January 19, 2011. http://www.gsk.com/media/pressreleases/2011/2011_pressrelease_10015.htm Accessed April 2011
    Google Scholar
  • 108 ClinicalTrials.gov .A study of intravenous zanamivir versus oral oseltamivir in adults and adolescents hospitalized with influenza. October 28, 2010. http://clinicaltrials.gov/ct2/show/NCT01231620?term=zanamivir+IV&rank=2 Accessed April 2011
    Google Scholar
  • 109 Kubo S, Tomozawa T, Kakuta M, Tokumitsu A, Yamashita M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.  Antimicrob Agents Chemother. 2010;  54 (3) 1256-1264
    CrossrefPubMedGoogle Scholar
  • 110 Koyama K, Takahashi M, Oitate M et al.. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.  Antimicrob Agents Chemother. 2009;  53 (11) 4845-4851
    CrossrefPubMedGoogle Scholar
  • 111 Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.  Antimicrob Agents Chemother. 2009;  53 (1) 186-192
    CrossrefPubMedGoogle Scholar
  • 112 Kubo S, Kakuta M, Yamashita M. In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses [in Japanese].  Jpn J Antibiot. 2010;  63 (5) 337-346
    PubMedGoogle Scholar
  • 113 Watanabe A, Chang S C, Kim M J, Chu D W, Ohashi Y. MARVEL Study Group . Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial.  Clin Infect Dis. 2010;  51 (10) 1167-1175
    CrossrefPubMedGoogle Scholar
  • 114 Ishizuka H, Yoshiba S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.  J Clin Pharmacol. 2010;  50 (11) 1319-1329
    PubMedGoogle Scholar
  • 115 Ishizuka H, Yoshiba S, Yoshihara K, Okabe H. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.  J Clin Pharmacol. 2011;  51 (2) 243-251
    PubMedGoogle Scholar
  • 116 Biota Holdings Ltd .LANI Phase III clinical trials in Asia prove successful. August 10, 2009. http://www.biota.com.au/uploaded/154/1021542_25laniphaseiiiclinicaltri.pdf Accessed February 2011
    Google Scholar
  • 117 Biota Holdings Ltd .Phase III trial with CS-8958 for flu prevention underway. November 5, 2009. http://www.biota.com.au/uploaded/154/1021585_54cs8958phaseiiipreventio.pdf Accessed February 2011
    Google Scholar
  • 118 Biota Holdings Ltd .Inavir® approved for sale in Japan. September 13, 2010. http://www.biota.com.au/uploaded/154/1021695_65inavirapprovedforsalein.pdf Accessed February 2011
    Google Scholar
  • 119 Hanessian S, Bayrakdarian M, Luo X. Total synthesis of A-315675: a potent inhibitor of influenza neuraminidase.  J Am Chem Soc. 2002;  124 (17) 4716-4721
    CrossrefPubMedGoogle Scholar
  • 120 Baz M, Abed Y, Nehmé B, Boivin G. Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.  Antimicrob Agents Chemother. 2009;  53 (2) 791-793
    CrossrefPubMedGoogle Scholar
  • 121 Rungrotmongkol T, Udommaneethanakit T, Frecer V, Miertus S. Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance.  Comb Chem High Throughput Screen. 2010;  13 (3) 268-277
    CrossrefPubMedGoogle Scholar
  • 122 Balfour Jr H H. Antiviral drugs.  N Engl J Med. 1999;  340 (16) 1255-1268
    CrossrefPubMedGoogle Scholar
  • 123 Brooks M J, Sasadeusz J J, Tannock G A. Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline?.  Curr Opin Pulm Med. 2004;  10 (3) 197-203
    CrossrefPubMedGoogle Scholar
  • 124 Sidwell R W, Bailey K W, Wong M H, Barnard D L, Smee D F. In vitro and in vivo influenza virus-inhibitory effects of viramidine.  Antiviral Res. 2005;  68 (1) 10-17
    CrossrefPubMedGoogle Scholar
  • 125 Kiso M, Takahashi K, Sakai-Tagawa Y et al.. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.  Proc Natl Acad Sci U S A. 2010;  107 (2) 882-887
    CrossrefPubMedGoogle Scholar
  • 126 Furuta Y, Takahashi K, Fukuda Y et al.. In vitro and in vivo activities of anti-influenza virus compound T-705.  Antimicrob Agents Chemother. 2002;  46 (4) 977-981
    CrossrefPubMedGoogle Scholar
  • 127 Furuta Y, Takahashi K, Kuno-Maekawa M et al.. Mechanism of action of T-705 against influenza virus.  Antimicrob Agents Chemother. 2005;  49 (3) 981-986
    CrossrefPubMedGoogle Scholar
  • 128 Sleeman K, Mishin V P, Deyde V M, Furuta Y, Klimov A I, Gubareva L V. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.  Antimicrob Agents Chemother. 2010;  54 (6) 2517-2524
    CrossrefPubMedGoogle Scholar
  • 129 Toyama Chemical Co., Ltd .Toyama Chemical Co., Ltd. initiates phase 2 clinical trial in the US of its anti-influenza drug candidate T-705. February 15, 2010. http://www.toyama-chemical.co.jp/eng/news/news100215e.html Accessed March 2011
    Google Scholar
  • 130 Belser J A, Lu X, Szretter K J et al.. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.  J Infect Dis. 2007;  196 (10) 1493-1499
    CrossrefPubMedGoogle Scholar
  • 131 Triana-Baltzer G B, Gubareva L V, Nicholls J M et al.. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.  PLoS ONE. 2009;  4 (11) e7788
    CrossrefPubMedGoogle Scholar
  • 132 Hedlund M, Aschenbrenner L M, Jensen K, Larson J L, Fang F. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection.  J Infect Dis. 2010;  201 (7) 1007-1015
    CrossrefPubMedGoogle Scholar
  • 133 Triana-Baltzer G B, Sanders R L, Hedlund M et al.. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.  J Antimicrob Chemother. 2011;  66 (1) 15-28
    CrossrefPubMedGoogle Scholar
  • 134 U.S. National Institutes of Health (NIH) .Randomized, double-blind, placebo controlled phase II study to examine the effects of DAS181 in healthy adult subjects with laboratory confirmed influenza. December 18, 2009. http://clinicaltrials.gov/ct2/show/NCT01037205?term=DAS181&rank=5 Accessed April 2011
    Google Scholar
  • 135 Ilyushina N A, Hoffmann E, Salomon R, Webster R G, Govorkova E A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.  Antivir Ther. 2007;  12 (3) 363-370
    PubMedGoogle Scholar
  • 136 Masihi K N, Schweiger B, Finsterbusch T, Hengel H. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.  J Chemother. 2007;  19 (3) 295-303
    PubMedGoogle Scholar
  • 137 Nguyen J T, Hoopes J D, Smee D F et al.. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.  Antimicrob Agents Chemother. 2009;  53 (10) 4115-4126
    CrossrefPubMedGoogle Scholar
  • 138 Nguyen J T, Hoopes J D, Le M H et al.. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.  PLoS ONE. 2010;  5 (2) e9332
    CrossrefPubMedGoogle Scholar
  • 139 Smee D F, Hurst B L, Wong M H et al.. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.  Antimicrob Agents Chemother. 2010;  54 (1) 126-133
    CrossrefPubMedGoogle Scholar
  • 140 Duval X, van der Werf S, Blanchon T Bivir Study Group et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.  PLoS Med. 2010;  7 (11) e1000362
    CrossrefPubMedGoogle Scholar
  • 141 Petersen E, Keld D B, Ellermann-Eriksen S et al.. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v.  Scand J Infect Dis. 2011 Feb 10. [Epub ahead of print]
    PubMedGoogle Scholar
  • 142 Cheung C Y, Poon L L, Lau A S et al.. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?.  Lancet. 2002;  360 (9348) 1831-1837
    CrossrefPubMedGoogle Scholar
  • 143 Peiris J S, Yu W C, Leung C W et al.. Re-emergence of fatal human influenza A subtype H5N1 disease.  Lancet. 2004;  363 (9409) 617-619
    CrossrefPubMedGoogle Scholar
  • 144 Chan M C, Cheung C Y, Chui W H et al.. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells.  Respir Res. 2005;  6 135
    CrossrefPubMedGoogle Scholar
  • 145 Kobasa D, Jones S M, Shinya K et al.. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus.  Nature. 2007;  445 (7125) 319-323
    CrossrefPubMedGoogle Scholar
  • 146 Ottolini M, Blanco J, Porter D, Peterson L, Curtis S, Prince G. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model.  Pediatr Pulmonol. 2003;  36 (4) 290-294
    CrossrefPubMedGoogle Scholar
  • 147 Zheng B J, Chan K W, Lin Y P et al.. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus.  Proc Natl Acad Sci U S A. 2008;  105 (23) 8091-8096
    CrossrefPubMedGoogle Scholar
  • 148 Budd A, Alleva L, Alsharifi M et al.. Increased survival after gemfibrozil treatment of severe mouse influenza.  Antimicrob Agents Chemother. 2007;  51 (8) 2965-2968
    CrossrefPubMedGoogle Scholar
  • 149 Henter J I, Palmkvist-Kaijser K, Holzgraefe B, Bryceson Y T, Palmér K. Cytotoxic therapy for severe swine flu A/H1N1.  Lancet. 2010;  376 (9758) 2116
    CrossrefPubMedGoogle Scholar
  • 150 Quispe-Laime A M, Bracco J D, Barberio P A et al.. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment.  Intensive Care Med. 2010;  36 (1) 33-41
    CrossrefPubMedGoogle Scholar
  • 151 Confalonieri M, Cifaldi R, Dreas L, Viviani M, Biolo M, Gabrielli M. Methylprednisolone infusion for life-threatening H1N1-virus infection.  Ther Adv Respir Dis. 2010;  4 (4) 233-237
    CrossrefPubMedGoogle Scholar
  • 152 Kidd I M, Down J, Nastouli E et al.. H1N1 pneumonitis treated with intravenous zanamivir.  Lancet. 2009;  374 (9694) 1036
    CrossrefPubMedGoogle Scholar
  • 153 Mishin V P, Hayden F G, Gubareva L V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.  Antimicrob Agents Chemother. 2005;  49 (11) 4515-4520
    CrossrefPubMedGoogle Scholar
  • 154 Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin M E, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.  N Engl J Med. 2009;  361 (23) 2296-2297
    CrossrefPubMedGoogle Scholar
  • 155 Hurt A C, Holien J K, Barr I G. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.  Antimicrob Agents Chemother. 2009;  53 (10) 4433-4440
    CrossrefPubMedGoogle Scholar
  • 156 Carr J, Ives J, Kelly L et al.. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.  Antiviral Res. 2002;  54 (2) 79-88
    CrossrefPubMedGoogle Scholar
  • 157 Gubareva L V, Robinson M J, Bethell R C, Webster R G. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.  J Virol. 1997;  71 (5) 3385-3390
    PubMedGoogle Scholar
  • 158 Abed Y, Baz M, Boivin G. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.  J Infect Dis. 2009;  199 (2) 180-183
    CrossrefPubMedGoogle Scholar
  • 159 Memoli M J, Hrabal R J, Hassantoufighi A, Eichelberger M C, Taubenberger J K. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.  Clin Infect Dis. 2010;  50 (9) 1252-1255
    CrossrefPubMedGoogle Scholar
  • 160 Okomo-Adhiambo M, Demmler-Harrison G J, Deyde V M et al.. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.  Antimicrob Agents Chemother. 2010;  54 (5) 1834-1841
    CrossrefPubMedGoogle Scholar

Guy BoivinM.D. 

Research Center in Infectious Diseases, Centre hospitalier Univeritaire de Quebec and Laval University

CHUL, Rm. RC-709, 2705 Blvd. Laurier, Sainte-Foy, Québec, Canada G1V 4G2

eMail: Guy.Boivin@crchul.ulaval.ca

      >